Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    Bexsero Pregnancy Registry
Previous Study | Return to List | Next Study

Safety of 4CMenB Exposure During Pregnancy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02640677
Recruitment Status : Active, not recruiting
First Posted : December 29, 2015
Last Update Posted : June 5, 2019
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Brief Summary:
4CMenB was approved by the Food and Drug Administration (FDA) in the United States in January 2015 for people aged 10 through 25 years of age. 4CMenB should be used during pregnancy only if clearly needed and sometimes, inadvertent exposure during pregnancy may also occur - before the woman knows she is pregnant, for example. The objective of this study is to evaluate the safety of 4CMenB during pregnancy and to help us learn more about the health of women who have been vaccinated with 4CMenB within 30 days prior to their last menstrual period (LMP) or at any time during pregnancy, and the health of their infants. Pregnant women within the US who received at least 1 dose 4CMenB vaccine within 30 days prior to their last menstrual period or at any time during pregnancy are eligible to participate. A woman may self-enroll in the registry by calling the pregnancy registry telephone number directly or their healthcare provider (HCP) can, with their consent, enroll them on their behalf. Alternatively HCPs may report anonymous data on pregnancy exposures and outcomes occurring within their network/health maintenance organization (HMO). The health of the woman and her infant will be followed up until the end of the pregnancy.

Condition or disease Intervention/treatment
Infections, Meningococcal Biological: 4CMenB

Layout table for study information
Study Type : Observational
Actual Enrollment : 1 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: 4CMenB Pregnancy Registry: an Observational Study of the Safety of 4CMenB Exposure in Pregnant Women and Their Offspring.
Actual Study Start Date : January 31, 2016
Estimated Primary Completion Date : November 30, 2019
Estimated Study Completion Date : November 30, 2019

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Pregnant women exposed to 4CMenB
Pregnant women within the US who received at least 1 dose of 4CMenB vaccine within 30 days prior to LMP or at any time during pregnancy
Biological: 4CMenB
This study is strictly observational; Administration of BEXSERO, the schedule of office visits and all treatment regimens will be determined by the treating health care provider in the context of routine clinical care.




Primary Outcome Measures :
  1. Major congenital malformation (MCM) [ Time Frame: at enrollment ]
  2. Major congenital malformation (MCM) [ Time Frame: end of 2nd trimester (approx. 24 weeks' gestation) ]
  3. Major congenital malformation (MCM) [ Time Frame: pregnancy outcome (delivery or early termination) ]
  4. Preterm birth [ Time Frame: at enrollment. ]
  5. Preterm birth [ Time Frame: end of 2nd trimester (approx. 24 weeks' gestation) ]
  6. Preterm birth [ Time Frame: pregnancy outcome (delivery or early termination) ]
  7. Low birth weight (LBW) [ Time Frame: at enrollment ]
  8. Low birth weight (LBW) [ Time Frame: end of 2nd trimester (approx. 24 weeks' gestation) ]
  9. Low birth weight (LBW) [ Time Frame: pregnancy outcome (delivery or early termination) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The study population will include pregnant women within the US who received at least 1 dose 4CMenB vaccine within 30 days prior to LMP or at any time during pregnancy.
Criteria

Inclusion Criteria:

Any pregnant women within the US who received at least 1 dose 4CMenB vaccine within 30 days prior to LMP or at any time during pregnancy where:

  • Sufficient evidence to confirm that exposure to a meningococcal B vaccine (confirmed or possible 4CMenB exposure) occurred within 30 days prior to LMP or at any time during pregnancy
  • Sufficient information to determine whether the pregnancy is prospectively or retrospectively registered (i.e., whether the outcome of pregnancy was known at the time of first contact with the registry)
  • Date the pregnancy exposure is registered
  • Full reporter (i.e., HCP) contact information to allow for follow-up (name, address, etc.)

Exclusion Criteria:

Pregnant women vaccinated with a different brand of Meningococcal B vaccine will not be included. (Of note: In the event that it cannot be ascertained to which meningococcal B vaccine the woman was exposed, an unknown exposure cohort will be established and analyzed separately).


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02640677


Locations
Layout table for location information
United States, North Carolina
GSK Investigational Site
Wilmington, North Carolina, United States, 28401-3331
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline

Layout table for additonal information
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT02640677     History of Changes
Other Study ID Numbers: 205533
V72_82OB ( Other Identifier: Novartis )
EUPAS 12183 ( Registry Identifier: EU PAS )
First Posted: December 29, 2015    Key Record Dates
Last Update Posted: June 5, 2019
Last Verified: June 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Meningococcal Infections
Neisseriaceae Infections
Gram-Negative Bacterial Infections
Bacterial Infections